The company celebrated the grand opening of the new EVO ICL Experience Center ... The company faces potential competitive pressure in China from new entrants in the implantable lens category. Q: Can ...

Our results reflect the increased global adoption and market share gains of EVO ICL lenses, the positive returns on our investments in commercial programs, our customer-focused initiatives ...

Our results reflect the increased global adoption and market share gains of EVO ICL lenses, the positive returns on our investments in commercial programs, our customer-focused initiatives, and the ...

Our results reflect the increased global adoption and market share gains of EVO ICL lenses, the positive returns on our investments in commercial programs, our customer-focused initiatives ...

The company is renowned for its EVO Implantable Collamer Lenses (EVO ICL™), which have been sold in over 75 countries. In its latest earnings report, STAAR Surgical announced a robust financial ...

manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended ...

LAKE FOREST, Calif., October 23, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, ...